BMS and Enterome collaborate over immuno-oncology
Bristol-Myers Squibb and Enterome, a pharmaceutical development and diagnostic company, have entered into a collaboration agreement focusing on immuno-oncology.
The collaboration centres on the development of “microbiome-derived biomarkers, drug targets and bioactive molecules” to be developed as potential companion diagnostics and therapeutics for cancer, said a statement from the companies.
Under the terms of the agreement, Bristol-Myers Squibb will be granted exclusive rights to intellectual property and therapies generated during the collaboration.
Enterome, a French company, will receive $15 million from Bristol-Myers Squibb as an upfront payment for access to its technology and research and development funding.
Carl Decicco, head of discovery at Bristol-Myers Squibb, said: “We continue to pursue the full potential of immuno-oncology by applying rapidly evolving science, technology and research to our strong foundation in harnessing the immune system to fight cancer.”
Pierre Belichard, CEO at Enterome, added: “The exciting combination of Bristol-Myers Squibb’s extensive capabilities in immuno-oncology with our expertise in identifying novel targets and molecules derived from the gut microbiome is highly complementary, and offers a unique opportunity to develop a new generation of cancer drugs and diagnostics.”
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk